← Back to Search

Radiopharmaceutical Diagnostic Imaging Agent

Parkinsonian Syndromes for Parkinson's Disease (POET-2 Trial)

Phase 3
Waitlist Available
Research Sponsored by Alseres Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 months
Awards & highlights

POET-2 Trial Summary

This trial will evaluate if 123I-ALTROPANE® paired with SPECT imaging can provide a more accurate early diagnosis of Parkinson's than clinical diagnosis alone.

Eligible Conditions
  • Parkinson's Disease

POET-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.
Secondary outcome measures
To evaluate the safety of 123 I-ALTROPANE® in subjects with upper extremity tremor for less than 2 years.

POET-2 Trial Design

2Treatment groups
Experimental Treatment
Group I: Parkinsonian SyndromesExperimental Treatment1 Intervention
Subjects with Parkinsonian Syndromes
Group II: Non-Parkinsonian SyndromesExperimental Treatment1 Intervention
Subjects with Non-Parkinsonian Syndromes

Find a Location

Who is running the clinical trial?

Alseres Pharmaceuticals, IncLead Sponsor
1 Previous Clinical Trials
54 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
2010. "Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00724906.
All > Aging
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top